drugset / Trial / NCT02793128

The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study

NCT02793128 ↗

Phase 3 Completed 71 enrolled UroGen Pharma Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The study is investigating the ability of UroGen's UGN-101 to treat urothelial carcinoma tumors from the upper urinary tract.

Timeline

Start
2017-04-04
Primary completion
2019-04-05
Completion
2020-03-05

Outcome

Met primary endpoint

paper 42 (59%, 95% CI 47-71; p<0·0001) patients had a complete response at the primary disease evaluation visit. PMID 32631491 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitomycin C Other / unclassified 4 mg/ml Other